Should You Retain Hologic Stock in Your Portfolio Now?

Zacks11-15 19:39

Hologic, Inc.’s HOLX robust strength in the Molecular Diagnostics business is poised to drive growth in the upcoming quarters. Solid demand for breast imaging solutions aids the Breast Health division...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483284376?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b","is_english":true,"pubTime":"2024-11-15 19:39","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483284376","market":"us","top_or_hot":-1,"title":"Should You Retain Hologic Stock in Your Portfolio Now?","media":"Zacks","content":"<div>\n<p>Hologic, Inc.’s HOLX robust strength in the Molecular Diagnostics business is poised to drive growth in the upcoming quarters. Solid demand for breast imaging solutions aids the Breast Health division...</p>\n\n<a href=\"https://finance.yahoo.com/news/retain-hologic-stock-portfolio-now-113900868.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Retain Hologic Stock in Your Portfolio Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Retain Hologic Stock in Your Portfolio Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/retain-hologic-stock-portfolio-now-113900868.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hologic, Inc.’s HOLX robust strength in the Molecular Diagnostics business is poised to drive growth in the upcoming quarters. Solid demand for breast imaging solutions aids the Breast Health division...</p>\n\n<a href=\"https://finance.yahoo.com/news/retain-hologic-stock-portfolio-now-113900868.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242649171.HKD","symbol_name":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/retain-hologic-stock-portfolio-now-113900868.html","article_id":"2483284376","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483284376","pubTimestamp":1731670740,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Hologic, Inc.’sHOLX robust strength in the Molecular Diagnostics business is poised to drive growth in the upcoming quarters. Solid demand for breast imaging solutions aids the Breast Health division’s growth, with the company’s new buyout further diversifying the business. On top of that, broad-based performance in the international markets is highly promising for the stock. Meanwhile, the uncertain macroeconomic volatilities as well as adverse currency fluctuations can dent Hologic’s operations.In the past year, this Zacks Rank #3  stock has risen 6.8% compared with the 19.9% growth of the industry and a 32.9% rise in the S&P 500.The renowned medical device company has a market capitalization of $18.39 billion. Hologic surpassed earnings estimates in all the trailing four quarters, delivering an average surprise of 3.07%.Focus on International Operations: Many of Hologic’s best-in-class products, such as ThinPrep Pap, 2D and 3D mammo tests, as well as NovaSure and MyoSure procedures,","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK4585":"ETF&股票定投概念","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","BK4588":"碎股","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","PEN":"Penumbra Inc","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","HOLX":"豪洛捷","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","BK4504":"桥水持仓","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","HAE":"美国血液技术","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BSX":"波士顿科学"},"translate_title":"您现在应该在投资组合中保留Hologic股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"BSX":1,"HOLX":1,"HAE":0.9},"content_text":"Hologic, Inc.’s HOLX robust strength in the Molecular Diagnostics business is poised to drive growth in the upcoming quarters. Solid demand for breast imaging solutions aids the Breast Health division’s growth, with the company’s new buyout further diversifying the business. On top of that, broad-based performance in the international markets is highly promising for the stock. Meanwhile, the uncertain macroeconomic volatilities as well as adverse currency fluctuations can dent Hologic’s operations.\nIn the past year, this Zacks Rank #3 (Hold) stock has risen 6.8% compared with the 19.9% growth of the industry and a 32.9% rise in the S&P 500.\nThe renowned medical device company has a market capitalization of $18.39 billion. Hologic surpassed earnings estimates in all the trailing four quarters, delivering an average surprise of 3.07%.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nFactors at Play\nMolecular Diagnostics Growth Continues: The molecular diagnostics segment has been a key driver for the division, contributing 13.2% (excluding COVID-19 sales) to the revenues in the fiscal fourth quarter of 2024. The impressive growth continues to be led by the BV/CV/TV assay and Biotheranostics business, offering significant growth potential.\nAdditionally, the respiratory COVID/Flu A/B/RSV assay contributed to the quarter’s performance. The company’s expanded global installed base of Panther instruments, which now surpassed 3,300 installations, represents the catalyst for the division's sustained growth. On top of this, the BV/CV/TV assay has grown to become the second largest worldwide due to its robust underlying strength.\nStrength in Breast Health: The business is thriving in the burgeoning spaces of radiology, breast surgery, pathology and treatment, with key profitable offerings such as 3D digital mammography systems, image analytics software utilizing artificial intelligence, ultrasound imaging and minimally invasive breast biopsy guidance systems.\nImage Source: Zacks Investment Research\nIn the fourth quarter of fiscal 2024, revenues increased 5.3% (excluding the divested SSI business and Endomagnetics), driven by increased breast imaging service revenues and contributions from the gantry business and interventional products.The Breast Health business has become more diversified, with the Endomagnetics suite of products, including Magseed markers, Magtrace lymphatic tracers and Sentimag. In addition, the company has collaborated with Bayer to deliver a coordinated solution for contrast-enhanced mammography, leveraging Hologic’s leading mammography technologies.\nFocus on International Operations: Many of Hologic’s best-in-class products, such as ThinPrep Pap, 2D and 3D mammo tests, as well as NovaSure and MyoSure procedures, hold a disproportionately low market share overseas while commanding a leading share in the domestic market. International sales have been a major catalyst for the company in the past few years, growing 5.4% year over year in the fourth quarter of fiscal 2024.\nThe Surgical business is driving strong, broad-based performance by expanding access to technologies into new global markets. Additionally, Hologic is expanding the Panther Fusion system’s global reach to meet the need for high-throughput molecular diagnostic respiratory testing and laying the groundwork to build an additional menu on the platform.\nFactors Affecting Hologic\nMacroeconomic Concerns: The effect of the worldwide political and social uncertainty, including the impact on trade regulations and tariffs, economic disruptions, as well as ongoing supply chain constraints, have reportedly hampered the costs and sales of Hologic’s products in certain countries in recent times.\nThese uncertainties surrounding global economic conditions and financial markets may cause medical equipment purchasers to decrease their medical health insurance premiums and procurement activities.High unemployment and health expenses may lead cost-conscious consumers to visit physicians less, adversely affecting the demand for the company’s products and procedures.\nForeign Exchange Headwinds: We remain worried about the significant challenges Hologic faced owing to unfavorable foreign currency impact that has been affecting the company’s overall performance in the past few quarters. The company’s international sales are often denominated in foreign currencies, including the Euro, U.K. Pound and Renminbi. Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of Hologic’s revenues outside the U.S. and associated cash flows.\nHOLX Stock Estimate Trend\nIn the past 30 days, the Zacks Consensus Estimate for Hologic’s fiscal 2025 earnings has moved south to $4.32 from $4.37.\nThe Zacks Consensus Estimate for HOLX’s fiscal 2024 revenues is pegged at $4.18 billion, suggesting a 3.7% rise from the year-ago reported number.\nKey MedTech Picks\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Boston Scientific BSX and Penumbra PEN.\nHaemonetics has an earnings yield of 3.39% compared to the industry’s 1.55% yield. Haemonetics’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 2.82%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year.\nHAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nBoston Scientific, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 13.8%. Shares of the company have surged 60.2% compared with the industry’s 23.1% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.29%.\nPenumbra, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 33.4% for 2024 compared with the industry’s 15.9%. Shares of Penumbra have risen 4.4% compared with the industry’s 20% growth over the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nHologic, Inc. (HOLX) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483284376"}